Aurora Cannabis Inc (TSE:ACB), CanniMed Therapeutics Inc (TSE:CMED) Deal Nearing Completion
Aurora announced that it has been successful in its offer to obtain all issued and outstanding common shares of CanniMed. This marks an important benchmark in the merger process because Aurora will own 17,847,341 shares—or approximately 70.66% of the total outstanding amount on a fully diluted basis—once shares are paid for not later than three business days after the CanniMed Shares are taken up.
CanniMed CEO Brent Zettl discusses the reasons why the merger shouldn’t proceed back in December 2017
As part of the deal, Aurora Cannabis will issue a total of approximately 50.6 million Aurora common shares and pay around $98 million is cash for CanniMed shares tendered as of March 8, 2018.
CanniMed now has until 11:59pm PST on March 25 to officially tender their shares and consummate the marriage. If that condition is not met, there’s no guarantee Aurora Cannabis will further extend its purchase offer, thus throwing merger plans in disarray. From everything the Midas Letter is hearing and reading however, chances of an impasse are virtually nil.
Given the timeline and official clearance by Aurora cannabis shareholders, the merger should officially be cemented in no more than 16 days time.
Aurora Executive Vice President explains why the Aurora takeover is good for CanniMed shareholders back in November, 2017
Full details of the Offer are available on SEDAR under CanniMed’s profile at www.sedar.com
What To Expect From The Combined Entity
On paper, the Aurora Cannabis-CanniMed Therapeutics merger is a big deal because it creates the biggest combined cannabis enterprise in Canada by market cap. Once consummated, the company will be valued at approximately $6.485 billion (current prices), eclipsing the Canopy Growth (TSE:WEED) market cap of $6.21 billion. For all intent and purposes, it creates two sector leaders in Canada, dethroning Canopy Growth as the ‘clear’ benchmark.
An Aurora-CanniMed entity will combine two of the leading international medicinal cannabis brands abroad. Aurora will pick up an additional 97,000 sq. ft. in production, to go along with the 820,000 sq.ft. in production it already has. Aurora also gains access to CanniMed’s sophisticated own quality control laboratories, Tier-1 productions facilities, and first-of-its-kind high-performance liquid chromatography methodology.
In a nutshell, Aurora Cannabis has turbo-charged it’s rapidly expanding medicinal cannabis portfolio. As an added bonus, the company’s immense growing power should lead to expanding profit margins on CanniMed’s refined goods. With 9-times the current production capacity of CanniMed—and a 1 million sq. ft. hybrid greenhouse planned in Denmark—Aurora has the scope to significantly reduce CanniMed’s existing input costs. It will be interesting to see how the combined entity’s margin costs play out down the line.
Following the merger, CEO Terry Booth expects a quick integration between both companies. “Following the take up, we will immediately commence with the integration of CanniMed into the Aurora organization and start executing on realizing the strategic synergies we have identified”.
The Midas Letter will have more coverage as the merger consummates and the new exchange listing approaches.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.